BREAKING: Abbott announces almost €40m R&D investment in Clonmel

Fantastic news

Abbott Vascular Care, Clonmel

Abbott's 250,000-square-foot facility on a 19-acre site on the Cashel Road, Clonmel.

Global healthcare company Abbott has announced further investment in its cardiovascular Research and Development Centre based at its vascular devices site in Clonmel.

Tipperary Senator and Seanad spokesperson for Enterprise and Trade, Garret Ahearn, welcomed the announcement and said: “I am delighted to see that Abbott has committed €37.8 million in its cardiovascular technologies R&D programme. This is a clear sign of commitment to Clonmel and the excellent workforce available in Tipperary. I congratulate the Irish and global teams on this investment and wish Abbott continued success in its operations here in Clonmel.”

Abbott is the world leader in drug-eluting stents. Both R&D and manufacturing of Abbott’s new vascular technologies to treat complex heart disease take place at its Clonmel site. The Irish R&D team spent three years developing the company’s market-leading stent, XIENCE Sierra, which is being used worldwide in patients who, because of the nature of their disease, might not previously have been suitable for minimally invasive surgery.

Abbott’s manufacturing plant in Clonmel manufactures its XIENCE family of stents, including XIENCE Sierra, for global use. The continued major investment programme in its R&D centre in Clonmel, supported by the Irish Government through IDA Ireland, comes as Abbott celebrates 75 years in Ireland this year.

Over the next three years, Abbott will invest €37.8 million in an R&D programme focusing on the discovery, innovation and development of a number of projects, including next generation drug eluting stents, as well as coronary and endovascular balloon technologies.

Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar, said: “Abbott was one of the first US companies to establish operations in Ireland and is one of our largest med-tech employers, with six manufacturing sites and three corporate services operations throughout the country. This announcement reflects Abbott’s ongoing commitment to Ireland. It is also a tribute to the management and staff of Abbott’s vascular division in Clonmel, who have played a pivotal role in the global success of Abbott’s XIENCE Sierra stent. I congratulate the Irish and global teams on this investment.”

Deirdre Mullins, site director, Abbott in Clonmel said: “Our market leading XIENCE stents were developed in Clonmel and this announcement places us at the vanguard of Abbott’s global research efforts in cardiovascular treatments. We are very proud that the life changing technologies we design and manufacture in Clonmel are saving lives in Ireland and across the world.”
CEO of IDA Ireland, Martin Shanahan, said: “Abbott has demonstrated real commitment to its Irish operations in its 75 years here, investing and expanding its operations and growing jobs across its manufacturing and shared services sites, employing over 4,000 people in Ireland.

“The economic and jobs benefit of Abbott’s longevity here is substantial. I congratulate the Irish and global teams on this investment and wish Abbott continued success in its operations here.” Abbott has six manufacturing facilities located in Clonmel, Cootehill, Donegal, Longford and Sligo and a third-party manufacturing management operation in Sligo.

Dr Diarmuid Meagher, Director of Research and Development, Abbott, explains that the engineering team worked closely with the global interventional cardiology community to understand the challenges that were impacting successful cardiovascular interventions. “We adapted the XIENCE design to develop a stent for older and more complex patients which was smaller, more flexible and physically stronger. Its sophisticated navigation makes it easier to manoeuvre through challenged arteries and obstacles and it’s now being used in 90 countries around the world.”

Buy the e-paper of the Donegal Democrat, Donegal People's Press, Donegal Post and Inish Times here for instant access to Donegal's premier news titles.

Keep up with the latest news from Donegal with our daily newsletter featuring the most important stories of the day delivered to your inbox every evening at 5pm.